690 logo

Uni-Bio Science Group Limited Stock Price

SEHK:690 Community·HK$435.9m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

690 Share Price Performance

HK$0
-0.15 (-100.00%)
HK$0
-0.15 (-100.00%)
Price HK$0

690 Community Narratives

There are no narratives available yet.

Trending Discussion

No trending discussion available.

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Excellent balance sheet with proven track record.

2 Risks
2 Rewards

Uni-Bio Science Group Limited Key Details

HK$586.2m

Revenue

HK$98.7m

Cost of Revenue

HK$487.6m

Gross Profit

HK$394.2m

Other Expenses

HK$93.3m

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
0.016
83.17%
15.92%
22.5%
View Full Analysis

About 690

Founded
2001
Employees
543
CEO
Zhi Gang Zhao
WebsiteView website
www.uni-bioscience.com

Uni-Bio Science Group Limited, an investment holding company, researches and develops, manufactures, and sells biological and chemical pharmaceutical products to treat human diseases in Hong Kong, and People’s Republic of China. It operates through Chemical Pharmaceutical Products, Biological Pharmaceutical Products, and Pipeline Products segments. The company provides BOGUTAI, a disposable injection pen for the treatment of osteoporosis; GeneTime, a prescription biological drug for wound healing; GeneSoft, a therapeutic drug for dry eye syndrome, corneal damage, and post-operative healing; Pinup, a voriconazole tablet to treat invasive aspergillosis and fungal infections; and Boshutai, for treating osteoporosis and bone pain. It also offers medical aesthetics. Uni-Bio Science Group Limited was incorporated in 2001 and is headquartered in Sha Tin, Hong Kong.

Recent 690 News & Updates

Recent updates

No updates